Opec chemotherapy (vincristine, prednisolone, etoposide and chlorambucil) for refractory and recurrent Hodgkin's disease
- 1 April 1987
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 5 (2) , 79-82
- https://doi.org/10.1002/hon.2900050202
Abstract
Fifteen adults with refractory or recurrent Hodgkin's disease were treated with a combination of: vincristine, prednisolone, etoposide and chlorambucil (OPEC). All had previously received mustine, vinblastine, procarbazine and prednisolone (MVPP) and seven had subsequently been treated with alternative regimens. Responses were achieved in four, but complete remission in only one. Toxicity was considerable and five died of treatment related complications. Only two are alive (one in complete remission) more than three years after therapy. The toxicity of the OPEC regimen outweighed its benefit in this group of poor prognosis patients.Keywords
This publication has 7 references indexed in Scilit:
- Five years' experience with Ch1VPP: Effective low-toxicity combination chemotherapy for Hodgkin's diseaseBritish Journal of Cancer, 1982
- Etoposide as a single agent in relapsed advanced lymphomasCancer Chemotherapy and Pharmacology, 1982
- Salvage Chemotherapy with ABVD in MOPP-Resistant Hodgkin's DiseaseAnnals of Internal Medicine, 1982
- Curability of Advanced Hodgkin's Disease with ChemotherapyAnnals of Internal Medicine, 1980
- Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP)Cancer Chemotherapy and Pharmacology, 1979
- MVPP chemotherapy regimen for advanced Hodgkin's diseaseBMJ, 1978
- Single-Agent Therapy for Hodgkin's DiseaseArchives of internal medicine (1960), 1973